SynteractHCR, a full-service, international contract research organization (CRO), will share its Phase I-IV clinical studies expertise with members of the global biopharmaceutical and life science communities by attending the 13th Annual Partnerships in Clinical Trials Congress (PCT Europe) on Nov. 5-6 in Barcelona, Spain. The team’s global clinical trial experts will be at booth #301 throughout the conference to meet with an international audience interested in discussing how both parties can work together to support all phases of clinical development.
Massimo Ildebrando, Director of Project Management for SynteractHCR Italia, will present on Thursday, November 6 at 17:15 on best practices for exploring how a sponsor and CRO can “build quality in” to vendor engagements for optimal clinical trial execution. He will cover key considerations for driving quality and efficiency in drug development, such as:
- Using Quality by Design (QbD) to properly assess and act on what’s critical to quality
- Creating quality standards for third-party engagements in clinical trials
- Leveraging sponsor governance and oversight activities to ensure the quality, time and cost drive continuous improvement
This 2014 PCT Europe conference marks two consecutive years that SynteractHCR is attending following the 2013 merger of San Diego-based Synteract with Munich-based Harrison Clinical Research (HCR).
“This is the second year our company will be at PCT Europe as an internationally-recognized brand,” said VP of Business Development Europe, Sebastien Duval. “Going into the conference, we feel more a part of the international community than ever. In fact, our teams have completed more than 3,400 different projects in 55 different countries and counting. As a member of the SynteractHCR attending this year’s PCT, I welcome the opportunity to further discuss how we can help clients in the European community run their trials worldwide.”
See SynteractHCR´s full schedule of events online, and follow its social channels on LinkedIn and Twitter for live updates during the PCT Europe conference.
About SynteractHCR (www.synteracthcr.com)
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and in more than 50 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy and Intelligent Clinical Development platform (ICD+), SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data so clients get to decision points faster.
